Business Description
Weleader Biomedical Co Ltd
ISIN : TW0007713000
Total Employee Number:
201Description
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.39 | |||||
Equity-to-Asset | 0.52 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 2.2 | |||||
Interest Coverage | 32.57 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.8 | |||||
Beneish M-Score | -2.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -6.5 | |||||
3-Year EBITDA Growth Rate | -0.7 | |||||
3-Year EPS without NRI Growth Rate | 1.4 | |||||
3-Year Book Growth Rate | 21.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.69 | |||||
9-Day RSI | 41.44 | |||||
14-Day RSI | 47.4 | |||||
3-1 Month Momentum % | 9.81 | |||||
6-1 Month Momentum % | 0.68 | |||||
12-1 Month Momentum % | 20.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.81 | |||||
Quick Ratio | 1.53 | |||||
Cash Ratio | 0.77 | |||||
Days Inventory | 57.85 | |||||
Days Sales Outstanding | 92.17 | |||||
Days Payable | 101.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.76 | |||||
Dividend Payout Ratio | 0.75 | |||||
Forward Dividend Yield % | 5.76 | |||||
5-Year Yield-on-Cost % | 5.77 | |||||
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -1.24 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 33.44 | |||||
Operating Margin % | 23.54 | |||||
Net Margin % | 18.8 | |||||
EBITDA Margin % | 35.44 | |||||
FCF Margin % | 8.97 | |||||
OCF Margin % | 28.24 | |||||
ROE % | 19.18 | |||||
ROA % | 9.4 | |||||
ROIC % | 12.57 | |||||
3-Year ROIIC % | 11.48 | |||||
ROC (Joel Greenblatt) % | 17.64 | |||||
ROCE % | 15.41 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 15.54 | |||||
PE Ratio without NRI | 15.55 | |||||
Price-to-Owner-Earnings | 17.33 | |||||
PEG Ratio | 1.85 | |||||
PS Ratio | 2.93 | |||||
PB Ratio | 2.53 | |||||
Price-to-Tangible-Book | 2.54 | |||||
Price-to-Free-Cash-Flow | 35.23 | |||||
Price-to-Operating-Cash-Flow | 10.56 | |||||
EV-to-EBIT | 13.81 | |||||
EV-to-EBITDA | 9.45 | |||||
EV-to-Revenue | 3.35 | |||||
EV-to-FCF | 37.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.85 | |||||
Price-to-Graham-Number | 1.32 | |||||
Earnings Yield (Greenblatt) % | 7.24 | |||||
FCF Yield % | 3.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Weleader Biomedical Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 1,109.3 | ||
| EPS (TTM) (NT$) | 4.51 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 15.47 | ||
| 14-Day RSI | 47.4 | ||
| 14-Day ATR (NT$) | 1.416735 | ||
| 20-Day SMA (NT$) | 71.115 | ||
| 12-1 Month Momentum % | 20.75 | ||
| 52-Week Range (NT$) | 61.3 - 83 | ||
| Shares Outstanding (Mil) | 45.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Weleader Biomedical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Weleader Biomedical Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 4.100000 Cash Dividend | 2026-03-27 | 73.50 (+0.00%) | ||
| TWD 3.368000 Cash Dividend | 2025-06-03 | 61.10 (-1.61%) |
Show
Entries
Weleader Biomedical Co Ltd Frequently Asked Questions
What is Weleader Biomedical Co Ltd(ROCO:7713)'s stock price today?
The current price of ROCO:7713 is NT$70.10. The 52 week high of ROCO:7713 is NT$83.00 and 52 week low is NT$61.30.
When is next earnings date of Weleader Biomedical Co Ltd(ROCO:7713)?
The next earnings date of Weleader Biomedical Co Ltd(ROCO:7713) is .
Does Weleader Biomedical Co Ltd(ROCO:7713) pay dividends? If so, how much?
The Dividend Yield %  of Weleader Biomedical Co Ltd(ROCO:7713) is 5.76% (As of Today), Highest Dividend Payout Ratio of Weleader Biomedical Co Ltd(ROCO:7713) was 0.75. The lowest was 0.56. And the median was 0.65. The  Forward Dividend Yield % of Weleader Biomedical Co Ltd(ROCO:7713) is 5.76%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Weleader Biomedical Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers